In this role, he will lead clinical development activities for Codiak's therapeutic candidates, starting with exoSTING and exoIL-12, for which clinical trials are anticipated to begin in 2020.
Benny Sorensen has more than 20 years of experience in clinical and translational research, and in his three-year tenure at Codiak, he has been a key member of the company's R and D leadership team.
Codiak BioSciences is harnessing exosomes, natural intercellular messengers, to pioneer a new class of biologic medicines, exosome therapeutics.
Brenner joins Codiak from Ononis Biosciences, where he was executive vice president and chief medical officer.
"Through groundbreaking scientific discovery and industrial development, Codiak is driving advancement of exosome biology for therapeutic applications," said Dr.